drugset
Drugs / AZD5396
last change Nov 2025 re-read 9 days ago

AZD5396

also known as dMAb AZD5396
Investigated by
AstraZeneca · Inovio Pharmaceuticals · Pablo Tebas · The Wistar Institute

Trials 1

today NCT05293249 · Ph 1
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05293249 May 2022 → Jun 2025 — Pablo Tebas Completed No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2025-10-21 Inovio Pharmaceuticals Results Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine inovio.com ↗
today announced results from a Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19 were published online in Nature Medicine under the title " Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial ."
2025-03-13 Inovio Pharmaceuticals Results INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 inovio.com ↗
In the trial, 100% (24/24) of participants who have reached week 72 maintained biologically relevant levels of DMAbs, confirming the durability of in vivo antibody production.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AZD5396 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293249 ↗
Known as dMAb AZD5396 “Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.” NCT05293249 ↗